531 related articles for article (PubMed ID: 28495264)
1. Community engagement and integrated health and polio immunisation campaigns in conflict-affected areas of Pakistan: a cluster randomised controlled trial.
Habib MA; Soofi S; Cousens S; Anwar S; Haque NU; Ahmed I; Ali N; Tahir R; Bhutta ZA
Lancet Glob Health; 2017 Jun; 5(6):e593-e603. PubMed ID: 28495264
[TBL] [Abstract][Full Text] [Related]
2. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
3. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
[TBL] [Abstract][Full Text] [Related]
4. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.
John J; Giri S; Karthikeyan AS; Iturriza-Gomara M; Muliyil J; Abraham A; Grassly NC; Kang G
Lancet; 2014 Oct; 384(9953):1505-12. PubMed ID: 25018120
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
6. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
[TBL] [Abstract][Full Text] [Related]
7. A Holistic Strategy of Mother and Child Health Care to Improve the Coverage of Routine and Polio Immunization in Pakistan: Results from a Demonstration Project.
Habib MA; Soofi SB; Hussain Z; Ahmed I; Tahir R; Anwar S; Nauman AA; Sharif M; Islam M; Cousens S; Bhutta ZA
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250902
[TBL] [Abstract][Full Text] [Related]
8. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis.
O'Reilly KM; Durry E; ul Islam O; Quddus A; Abid N; Mir TP; Tangermann RH; Aylward RB; Grassly NC
Lancet; 2012 Aug; 380(9840):491-8. PubMed ID: 22766207
[TBL] [Abstract][Full Text] [Related]
9. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
Khan MM; Sharma S; Tripathi B; Alvarez FP
Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
[TBL] [Abstract][Full Text] [Related]
10. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.
Mir F; Quadri F; Mach O; Ahmed I; Bhatti Z; Khan A; Rehman NU; Durry E; Salama M; Oberste SM; Weldon WC; Sutter RW; Zaidi AK
Lancet Infect Dis; 2015 Aug; 15(8):889-97. PubMed ID: 26093979
[TBL] [Abstract][Full Text] [Related]
11. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
[TBL] [Abstract][Full Text] [Related]
12. Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization.
Sarnquist C; Holubar M; García-García L; Ferreyra-Reyes L; Delgado-Sánchez G; Cruz-Hervert LP; Montero-Campos R; Altamirano J; Purington N; Boyle S; Modlin J; Ferreira-Guerrero E; Canizales-Quintero S; Díaz Ortega JL; Desai M; Maldonado YA
Clin Infect Dis; 2018 Oct; 67(suppl_1):S115-S120. PubMed ID: 30376084
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
[TBL] [Abstract][Full Text] [Related]
14. Determinants of immunization in polio super high-risk union councils of Pakistan.
Khan A; Hussain I; Rhoda DA; Umer M; Ansari U; Ahmed I; Clary C; Muhammad Safdar R; Bashir Soofi S
Vaccine; 2024 Jan; 42(3):583-590. PubMed ID: 38143197
[TBL] [Abstract][Full Text] [Related]
15. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
16. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
17. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).
Prevots DR; Burr RK; Sutter RW; Murphy TV;
MMWR Recomm Rep; 2000 May; 49(RR-5):1-22; quiz CE1-7. PubMed ID: 15580728
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P
Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429
[TBL] [Abstract][Full Text] [Related]
19. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
[TBL] [Abstract][Full Text] [Related]
20. Mass immunization with inactivated polio vaccine in conflict zones--Experience from Borno and Yobe States, North-Eastern Nigeria.
Shuaibu FM; Birukila G; Usman S; Mohammed A; Galway M; Corkum M; Damisa E; Mkanda P; Mahoney F; Wa Nganda G; Vertefeuille J; Chavez A; Meleh S; Banda R; Some A; Mshelia H; Umar AU; Enemaku O; Etsano A
J Public Health Policy; 2016 Feb; 37(1):36-50. PubMed ID: 26538455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
